<p>在 Google 搜索和 AI 回答中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开 Google</p>
<p>在 Google 上添加</p>
<p>迈阿密 --（商业新闻）--Summit Therapeutics Inc.（纳斯达克：SMMT）（“Summit”，“我们” 或 “公司”）今天宣布已开始进行 5 亿美元的普通股承销公开发行。所有拟议发行的股份均由 Summit 提供。此外，Summit 打算授予承销商一个 30 天的选择权，以按公开发行价格购买最多 7500 万美元的普通股，扣除承销折扣和佣金。拟议的发行受市场和其他条件的限制，无法保证发行是否或何时完成，或发行的实际规模或条款。</p>
<p>Summit 打算将拟议发行的净收益与现有现金、现金等价物一起用于其主要产品候选药物 ivonescimab 的研究和开发，以及用于营运资金和其他一般企业用途。</p>
<p>摩根大通、高盛公司和花旗集团作为拟议发行的联合账簿管理人。</p>
<p>上述证券是根据已向证券交易委员会（SEC）提交的 S-3 表格的货架注册声明进行发行的，包括之前提交的基本招股说明书，该注册声明于 2026 年 6 月 9 日自动生效。与拟议发行相关的初步招股说明书补充及其基本招股说明书将提交给 SEC，并将在 SEC 的网站 www.sec.gov 上提供。初步招股说明书补充及其基本招股说明书的副本也可以在可用时从以下地址获取：摩根大通证券公司，c/o Broadridge Financial Solutions，1155 Long Island Avenue，Edgewood，NY 11717，或通过电子邮件发送至 prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；高盛公司，注意：招股说明书部门，200 West Street，New York，NY 10282，电话（866）471-2526，或通过电子邮件发送至 Prospectus-ny@ny.email.gs.com；或花旗集团，c/o Broadridge Financial Solutions，1155 Long Island Avenue，Edgewood，NY 11717，或电话（800）831-9146。</p>
<p>本新闻稿不构成出售要约或购买要约的招揽，也不应在任何州或司法管辖区内进行这些证券的销售，除非在任何此类州或司法管辖区的证券法下注册或合格之前。</p>
<p><strong>关于 Summit Therapeutics</strong></p>
<p>Summit Therapeutics Inc.是一家生物制药肿瘤公司，专注于发现、开发和商业化以患者、医生、护理人员和社会为中心的药物疗法，旨在改善生活质量、延长潜在寿命并解决严重的未满足医疗需求。</p>
<p>Summit 成立于 2003 年，我们的股票在纳斯达克全球市场上市（代码 “SMMT”）。我们总部位于佛罗里达州迈阿密，并在加利福尼亚州帕洛阿尔托、新泽西州普林斯顿、爱尔兰都柏林和英国牛津设有其他办公室。</p>
<p>欲了解更多信息，请访问 https://www.smmttx.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中关于市场条件相关的不确定性以及关于发行的时间、规模和预期总收益的声明，关于满足与证券发行和销售相关的惯例成交条件的声明，授予承销商购买额外股份的选择权的声明，以及公司完成发行的能力的声明，以及包含 “预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“会” 等类似表达的其他声明，构成 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有重大差异，包括影响资本市场的条件和与拟议公开发行相关的成交条件的满足，授予承销商购买额外股份的选择权，拟议发行的时间和规模，以及 Summit 计划使用其收益的方式，整体经济、行业或政治条件，关于 ivonescimab 开发和商业化活动的基础数据评估结果，与监管机构（包括食品和药物管理局）的讨论结果，未来临床试验启动中固有的不确定性，正在进行和未来临床试验的数据的可用性和时间，试验结果及其成功，以及可能影响我们临床试验和运营的全球公共卫生危机，初步临床试验结果是否能预测该试验的最终结果，或早期临床试验或临床前研究的结果是否能指示后续临床试验的结果，是否有商业发展机会扩展公司的药物候选人管道，包括但不限于通过潜在收购和/或与其他实体的合作，监管批准的预期，影响政府合同和资金奖励的法律法规，足够的资金可用于公司可预见和不可预见的运营费用和资本支出要求，以及公司向 SEC 提交的文件中 “风险因素” 部分讨论的其他因素。对我们正在进行的试验的任何变更可能导致延迟，影响我们未来的费用，并增加我们商业化努力的不确定性，同时影响 ivonescimab 临床开发成功完成的可能性。因此，读者不应对前瞻性声明或信息过于依赖。此外，本新闻稿中包含的任何前瞻性声明仅代表公司在本发布日期的观点，不应被视为公司在任何后续日期的观点。公司特别声明不承担更新本新闻稿中包含的任何前瞻性声明的义务。有关可能导致实际结果与这些前瞻性声明所表达的结果不同的风险和不确定性的进一步描述，以及与公司业务相关的风险，请参见本次发行的招股说明书补充及相关招股说明书，以及公司提交给 SEC 的 10-K 表格年度报告、10-Q 表格季度报告及其他报告。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA2MDk5NjQzNDZyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA2MDk5NjQzNDZyMQ"/></p>
<p>查看源版本请访问 businesswire.com: https://www.businesswire.com/news/home/20260609964346/en/</p>
<p><strong>联系 Summit 投资者关系：</strong></p>
<p>Dave Gancarz</p>
<p>首席商务与战略官</p>
<p>Nathan LiaBraaten</p>
<p>投资者关系高级总监</p>
<p>investors@smmttx.com</p>
<p>来源：Summit Therapeutics</p>

Summit治疗

GS-A

高盛

花旗

GS-C

摩根大通

JPMO

<p>Summit Therapeutics（纳斯达克代码：SMMT）宣布进行一项 5 亿美元的普通股承销公开发行，承销商有 30 天的选择权可购买额外 7500 万美元的股票。摩根大通、高盛和花旗担任联合账簿管理人。该公司计划将净收益与现有现金一起用于其主要产品候选药物 ivonescimab 的研发，以及一般企业用途</p>

<p>See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google</p>
<div class="lb-trans"><p>在 Google 搜索和 AI 回答中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开 Google</p>
</div><p>Add on Google</p>
<div class="lb-trans"><p>在 Google 上添加</p>
</div><p>MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Summit. In addition, Summit intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p>
<div class="lb-trans"><p>迈阿密 --（商业新闻）--Summit Therapeutics Inc.（纳斯达克：SMMT）（“Summit”，“我们” 或 “公司”）今天宣布已开始进行 5 亿美元的普通股承销公开发行。所有拟议发行的股份均由 Summit 提供。此外，Summit 打算授予承销商一个 30 天的选择权，以按公开发行价格购买最多 7500 万美元的普通股，扣除承销折扣和佣金。拟议的发行受市场和其他条件的限制，无法保证发行是否或何时完成，或发行的实际规模或条款。</p>
</div><p>Summit intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents, to fund the research and development of its lead product candidate, ivonescimab, and for working capital and other general corporate purposes.</p>
<div class="lb-trans"><p>Summit 打算将拟议发行的净收益与现有现金、现金等价物一起用于其主要产品候选药物 ivonescimab 的研究和开发，以及用于营运资金和其他一般企业用途。</p>
</div><p>J.P. Morgan, Goldman Sachs &amp; Co. LLC and Citigroup are acting as joint book-running managers for the proposed offering.</p>
<div class="lb-trans"><p>摩根大通、高盛公司和花旗集团作为拟议发行的联合账簿管理人。</p>
</div><p>The securities described above are being offered by Summit pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (SEC) and which became automatically effective on June 9, 2026. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus may also be obtained, when available, from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Goldman Sachs &amp; Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at Prospectus-ny@ny.email.gs.com; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146.</p>
<div class="lb-trans"><p>上述证券是根据已向证券交易委员会（SEC）提交的 S-3 表格的货架注册声明进行发行的，包括之前提交的基本招股说明书，该注册声明于 2026 年 6 月 9 日自动生效。与拟议发行相关的初步招股说明书补充及其基本招股说明书将提交给 SEC，并将在 SEC 的网站 www.sec.gov 上提供。初步招股说明书补充及其基本招股说明书的副本也可以在可用时从以下地址获取：摩根大通证券公司，c/o Broadridge Financial Solutions，1155 Long Island Avenue，Edgewood，NY 11717，或通过电子邮件发送至 prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；高盛公司，注意：招股说明书部门，200 West Street，New York，NY 10282，电话（866）471-2526，或通过电子邮件发送至 Prospectus-ny@ny.email.gs.com；或花旗集团，c/o Broadridge Financial Solutions，1155 Long Island Avenue，Edgewood，NY 11717，或电话（800）831-9146。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售要约或购买要约的招揽，也不应在任何州或司法管辖区内进行这些证券的销售，除非在任何此类州或司法管辖区的证券法下注册或合格之前。</p>
</div><p><strong>About Summit Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Summit Therapeutics</strong></p>
</div><p>Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.</p>
<div class="lb-trans"><p>Summit Therapeutics Inc.是一家生物制药肿瘤公司，专注于发现、开发和商业化以患者、医生、护理人员和社会为中心的药物疗法，旨在改善生活质量、延长潜在寿命并解决严重的未满足医疗需求。</p>
</div><p>Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol “SMMT”). We are headquartered in Miami, Florida, and we have additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK.</p>
<div class="lb-trans"><p>Summit 成立于 2003 年，我们的股票在纳斯达克全球市场上市（代码 “SMMT”）。我们总部位于佛罗里达州迈阿密，并在加利福尼亚州帕洛阿尔托、新泽西州普林斯顿、爱尔兰都柏林和英国牛津设有其他办公室。</p>
</div><p>For more information, please visit https://www.smmttx.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 https://www.smmttx.com。</p>
</div><p><strong>Forward-looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Any statements in this press release about uncertainties related to market conditions and statements regarding the timing, size and expected gross proceeds of the offering, the satisfaction of customary closing conditions related to the offering and sale of securities, the grant to the underwriters of an option to purchase additional shares and the Company’s ability to complete the offering, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including conditions affecting the capital markets and the satisfaction of closing conditions related to the proposed public offering, the grant to the underwriters of the option to purchase additional shares, timing and size of the proposed offering and Summit’s intended use of proceeds therefrom, general economic, industry, or political conditions, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, and global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company’s pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of filings that the Company makes with the SEC. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see the prospectus supplement and related prospectus for this offering as well as the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and its other reports filed with the SEC.</p>
<div class="lb-trans"><p>本新闻稿中关于市场条件相关的不确定性以及关于发行的时间、规模和预期总收益的声明，关于满足与证券发行和销售相关的惯例成交条件的声明，授予承销商购买额外股份的选择权的声明，以及公司完成发行的能力的声明，以及包含 “预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“会” 等类似表达的其他声明，构成 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有重大差异，包括影响资本市场的条件和与拟议公开发行相关的成交条件的满足，授予承销商购买额外股份的选择权，拟议发行的时间和规模，以及 Summit 计划使用其收益的方式，整体经济、行业或政治条件，关于 ivonescimab 开发和商业化活动的基础数据评估结果，与监管机构（包括食品和药物管理局）的讨论结果，未来临床试验启动中固有的不确定性，正在进行和未来临床试验的数据的可用性和时间，试验结果及其成功，以及可能影响我们临床试验和运营的全球公共卫生危机，初步临床试验结果是否能预测该试验的最终结果，或早期临床试验或临床前研究的结果是否能指示后续临床试验的结果，是否有商业发展机会扩展公司的药物候选人管道，包括但不限于通过潜在收购和/或与其他实体的合作，监管批准的预期，影响政府合同和资金奖励的法律法规，足够的资金可用于公司可预见和不可预见的运营费用和资本支出要求，以及公司向 SEC 提交的文件中 “风险因素” 部分讨论的其他因素。对我们正在进行的试验的任何变更可能导致延迟，影响我们未来的费用，并增加我们商业化努力的不确定性，同时影响 ivonescimab 临床开发成功完成的可能性。因此，读者不应对前瞻性声明或信息过于依赖。此外，本新闻稿中包含的任何前瞻性声明仅代表公司在本发布日期的观点，不应被视为公司在任何后续日期的观点。公司特别声明不承担更新本新闻稿中包含的任何前瞻性声明的义务。有关可能导致实际结果与这些前瞻性声明所表达的结果不同的风险和不确定性的进一步描述，以及与公司业务相关的风险，请参见本次发行的招股说明书补充及相关招股说明书，以及公司提交给 SEC 的 10-K 表格年度报告、10-Q 表格季度报告及其他报告。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA2MDk5NjQzNDZyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260609964346r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260609964346/en/</p>
<div class="lb-trans"><p>查看源版本请访问 businesswire.com: https://www.businesswire.com/news/home/20260609964346/en/</p>
</div><p><strong>Contact Summit Investor Relations:</strong></p>
<div class="lb-trans"><p><strong>联系 Summit 投资者关系：</strong></p>
</div><p>Dave Gancarz</p>
<div class="lb-trans"><p>Dave Gancarz</p>
</div><p>Chief Business &amp; Strategy Officer</p>
<div class="lb-trans"><p>首席商务与战略官</p>
</div><p>Nathan LiaBraaten</p>
<div class="lb-trans"><p>Nathan LiaBraaten</p>
</div><p>Senior Director, Investor Relations</p>
<div class="lb-trans"><p>投资者关系高级总监</p>
</div><p>investors@smmttx.com</p>
<div class="lb-trans"><p>investors@smmttx.com</p>
</div><p>Source: Summit Therapeutics</p>
<div class="lb-trans"><p>来源：Summit Therapeutics</p>
</div>

Summit 治疗公司宣布拟公开发行普通股 | SMMT 股票新闻